BioAlliance's acyclovir Lauriad positive in Phase III
This article was originally published in Scrip
Executive Summary
BioAlliance Pharma has announced positive top-line data of a pivotal Phase III study of its antiviral acyclovir Lauriad for the treatment of herpes labialis.